Breaking News Instant updates and real-time market news.

DKS

Dick's Sporting

$27.57

0.7 (2.61%)

, TEVA

Teva

$17.78

-0.19 (-1.06%)

10:37
08/16/17
08/16
10:37
08/16/17
10:37

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dick's Sporting (DKS) was downgraded to Neutral from Buy at Monness Crespi, Goldman Sachs, MKM Partners, Buckingham, Citi, and to Neutral from Positive at Susquehanna, while being downgraded to Hold from Buy at Deutsche Bank and to Sector Perform from Outperform at RBC Capital. 2. Teva (TEVA) downgraded to Neutral from Buy at Citi with analyst Liav Abraham saying Teva is "cheap, but not cheap enough." 3. Advance Auto Parts (AAP) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing limited near-term visibility. 4. SL Green Realty (SLG) and Kilroy Realty (KRC) were downgraded to Neutral from Buy at BofA/Merrill, while Gramercy Property Trust (GPT) was downgraded to Underperform from Neutral. 5. CB&I (CBI) downgraded to Hold from Buy at Jefferies with analyst Martin Englert saying he is concerned that cost overruns at the company's two LNG projects could reemerge, adding risk to 2017-2019 earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

DKS

Dick's Sporting

$27.57

0.7 (2.61%)

TEVA

Teva

$17.78

-0.19 (-1.06%)

AAP

Advance Auto Parts

$88.57

1.49 (1.71%)

SLG

SL Green Realty

$99.52

0.05 (0.05%)

KRC

Kilroy Realty

$69.90

-0.07 (-0.10%)

GPT

Gramercy Property Trust

$29.15

-0.32 (-1.09%)

CBI

CB&I

$10.59

-0.605 (-5.41%)

  • 22

    Aug

  • 23

    Aug

  • 30

    Aug

DKS Dick's Sporting
$27.57

0.7 (2.61%)

08/16/17
MONN
08/16/17
DOWNGRADE
MONN
Neutral
Dick's Sporting downgraded to Neutral from Buy at Monness Crespi
Monness Crespi analyst Jim Chartier downgraded Dick's Sporting Goods to Neutral following the company's Q2 results.
08/16/17
SUSQ
08/16/17
DOWNGRADE
Target $30
SUSQ
Neutral
Dick's Sporting downgraded to Neutral from Positive at Susquehanna
Susquehanna analyst Sam Poser downgraded Dick's Sporting Goods to Neutral and cut his price target for the shares to $30 from $57 following the company's Q2 results.
08/16/17
GSCO
08/16/17
DOWNGRADE
Target $30
GSCO
Neutral
Dick's Sporting downgraded to Neutral from Buy at Goldman Sachs
Goldman analyst Stephen Tanal downgraded Dick's Sporting Goods to Neutral and slashed its price target to $30 from $49 following the Q2 report and reduced outlook resulting in a reduction in forecasts.
08/16/17
MKMP
08/16/17
DOWNGRADE
MKMP
Neutral
Dick's Sporting downgraded to Neutral from Buy at MKM Partners
MKM Partners analyst Patrick McKeever,downgraded Dick's, saying that the company's results appear to have deteriorated significantly during the course of Q2. The analyst says that the company was hurt by increased promotion and wider distribution of key brands by competitors. Target $30.
TEVA Teva
$17.78

-0.19 (-1.06%)

08/16/17
SBSH
08/16/17
DOWNGRADE
Target $19
SBSH
Neutral
Teva downgraded to Neutral from Buy at Citi
Citi analyst Liav Abraham downgraded Teva Pharmaceutical (TEVA) to Neutral and cut her price target for the shares to $19 from $32. The analyst this morning also upgraded Mylan (MYL) to Buy. Teva is "cheap, but not cheap enough," Abraham tells investors in a research note. She needs to see the appointment of a "respected" CEO and formulation of a credible long-term strategy as well as improvement in the credit situation before getting more constructive on Teva shares.
08/16/17
SBSH
08/16/17
UPGRADE
Target $42
SBSH
Buy
Mylan upgraded to Buy from Neutral at Citi
Citi analyst Liav Abraham upgraded Mylan (MYL) to Buy and raised her price target for the shares to $42 from $36. The company is best positioned to execute in a challenging operating environment for generics, Abraham tells investors in a research note. Mylan has a "differentiated and durable" generics product portfolio, "broad pipeline" of complex generics/ biosimilars and a more favorable balance sheet profile relative to peers, the analyst contends. She has Neutral ratings on Teva (TEVA) and Endo (ENDP).
08/07/17
08/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he underappreciated generic pricing pressure risks on Teva's dividend and expects declining earnings power, combined with high leverage equal to result in a longer recovery. 2. Cummins (CMI) downgraded to Buy from Conviction Buy at Goldman Sachs. 3. RE/MAX Holdings (RMAX) downgraded to Equal Weight from Overweight at Stephens. 4. Intrepid Potash (IPI) downgraded to Sell from Neutral at UBS with analyst John Roberts saying that while bankruptcy risk has been "significantly reduced" since the share count was increased 60% with the March secondary, he remains concerned about the lack of long term growth in non-core income and "still depressed" core potash related income. Roberts cites valuation for his downgrade and raised his price target for Intrepid Potash shares to $2.50 from $2.00. 5. Eaton (ETN) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/17
MSCO
08/07/17
DOWNGRADE
Target $16
MSCO
Teva downgraded to Underweight, bear case target $9 at Morgan Stanley
As previously reported, Morgan Stanley downgraded Teva to Underweight from Equal Weight and cut its price target to $16 from $36. Analyst David Risinger said he underappreciated generic pricing pressure risks on Teva's dividend and expects declining earnings power, combined with high leverage equal to result in a longer recovery. He expects core business generic headwinds and Copaxone generic competition to pressure Teva's long-term earnings power and cut his 2017 earnings estimate to $1.24 from $1.55, 2018 earnings estimate to $4.14 from $4.56, and 2019 earnings estimate to $3.79 from $4.50. Risinger's bear case price target on Teva is $9, which assumes much more severe Copaxone erosion and generic business downside.
AAP Advance Auto Parts
$88.57

1.49 (1.71%)

08/16/17
GABE
08/16/17
NO CHANGE
GABE
Buy
Advance Auto Parts weakness a buying opportunity, says Gabelli
08/16/17
DBAB
08/16/17
NO CHANGE
Target $101
DBAB
Buy
Deutsche Bank sticking with Buy rating on Advance Auto Parts
Deutsche Bank analyst Mike Baker lowered his price target to $101 from $139 following the Q2 results but is sticking with his Buy rating on Advance Auto Parts. First and most importantly, the company seems to be stabilizing its market share, the first step in any turnaround, Baker tells investors in a post-earnings research note. He also believes downward earnings revisions should be behind the company and that the current share price assumes little margin recovery.
08/16/17
ATLE
08/16/17
DOWNGRADE
Target $93
ATLE
Neutral
Advance Auto Parts downgraded to Neutral from Overweight at Atlantic Equities
Atlantic Equities analyst Sam Hudson downgraded Advance Auto Parts to Neutral from Overweight with a $93 price target citing limited near-term visibility. Hudson said the challenging industry backdrop has pushed out a turnaround until FY18 at the earliest and said negative comps will persist in the second half and near-term margins are difficult to gauge.
08/16/17
JPMS
08/16/17
NO CHANGE
Target $106
JPMS
Overweight
Advance Auto Parts price target lowered to $106 from $180 at JPMorgan
JPMorgan analyst Christopher Horvers lowered his price target for Advance Auto Parts to $106 following the company's Q2 results. The analyst expects the inventory cost pressures to continue until inventory per store stabilizes, which he doesn't see until 2019. Horvers believes he and management underappreciated how much investment in the turnaround. He keeps an Overweight rating on Advance Auto.
SLG SL Green Realty
$99.52

0.05 (0.05%)

07/13/17
UBSW
07/13/17
UPGRADE
UBSW
Buy
SL Green Realty upgraded to Buy from Neutral at UBS
07/13/17
UBSW
07/13/17
UPGRADE
Target $117
UBSW
Buy
SL Green Realty upgraded to Buy at UBS
As reported previously, UBS analyst Nick Yulico upgraded SL Green Realty to Buy from Neutral. The analyst believes NYC Office fundamentals are better than the sentiment on the stock and that 2018 will see occupancy improvement and rent growth from rolling below-market leases. Yulico maintained his $117 price target on SL Green Realty shares.
08/16/17
BOFA
08/16/17
DOWNGRADE
Target $110
BOFA
Neutral
SL Green Realty downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst James Feldman downgraded SL Green Realty to Neutral and lowered its price target to $110 from $113. The analyst is trimming exposure to New York City given incremental concerns over rent growth and asset prices.
06/22/17
GSCO
06/22/17
INITIATION
Target $121
GSCO
Buy
SL Green Realty resumed with a Buy at Goldman Sachs
Goldman analyst Andrew Rosivach resumed SL Green Realty with a Buy and a $121 price target given earnings growth and relative valuation.
KRC Kilroy Realty
$69.90

-0.07 (-0.10%)

03/03/17
EVER
03/03/17
DOWNGRADE
EVER
Underperform
Kilroy Realty downgraded to Underperform from Hold at Evercore ISI
03/28/17
EVER
03/28/17
UPGRADE
Target $76
EVER
In Line
Kilroy Realty upgraded to In Line from Underperform at Evercore ISI
Evercore ISI analyst Steve Sakwa upgraded Kilroy Realty to In Line and maintained its $76 price target following the recent decline and underperformance of shares relative to the broader REIT sector.
08/14/17
EVER
08/14/17
UPGRADE
Target $78
EVER
Outperform
Kilroy Realty upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Steve Sakwa upgraded Kilroy Realty to Outperform and maintained a $78 price target saying shares are too cheap relative to existing fundamentals and future growth, and expects issues with the Exchange at Mission Bay development project to be resolved within 6-9 months.
08/16/17
BOFA
08/16/17
DOWNGRADE
Target $77
BOFA
Neutral
Kilroy Realty downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst James Feldman downgraded Kilroy Realty to Neutral and lowered its price target to $77 from $80. The analyst believes the impact from known 2018 move outs is reflected in consensus estimates and expects it to weigh on 2018 and 2019 same-store growth. Further, Feldman expects San Diego could be a drag compared to peers.
GPT Gramercy Property Trust
$29.15

-0.32 (-1.09%)

01/09/17
JMPS
01/09/17
DOWNGRADE
JMPS
Market Perform
Gramercy Property Trust downgraded to Market Perform at JMP Securities
12/05/16
BOFA
12/05/16
DOWNGRADE
BOFA
Neutral
Gramercy Property Trust downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst James Feldman downgraded Gramercy Property Trust to Neutral due to the rise in the cost of capital and limited upside from accelerating GDP growth given long lease terms of triple nets.
11/02/16
11/02/16
NO CHANGE

Gramercy Property Trust appoints Nicholas Pell as Chief Investment Officer
Gramercy Property Trust appointed Nicholas L. Pell as Chief Investment Officer. Previously, Pell was a Managing Director with Gramercy. His appointment is effective immediately.
08/16/17
BOFA
08/16/17
DOWNGRADE
BOFA
Underperform
Gramercy Property Trust downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst James Feldman downgraded Gramercy Property Trust to Underperform citing relative valuation and headwinds in its industrial portfolio.
CBI CB&I
$10.59

-0.605 (-5.41%)

08/16/17
AGIS
08/16/17
NO CHANGE
Target $77
AGIS
Buy
W.R. Grace could rally $10 on CB&I unit acquisition, says Aegis
Aegis analyst Chris Kapsch believes Grace (GRA) is likely to become bigger via acquisitions and that CB&I's (CBI) process technology licensing division is a potential target. CB&I is a highly motivated seller, looking to complete the divestiture by year end, Kapsch tells investors in a research note. He believes Grace may be willing to pay as much as $1.5B for the asset and his "rough math" suggests such a deal could be 55c-60c accretive in FY18. This sort of deal accretion could be worth as much as $10 per share for Grace's equity, Kapsch argues. He has a Buy rating on Grace with a $77 price target.
08/16/17
JEFF
08/16/17
DOWNGRADE
Target $12
JEFF
Hold
CB&I downgraded to Hold from Buy at Jefferies
Jefferies analyst Martin Englert downgraded CB&I to Hold and cut his price target for the shares to $12 from $35. The analyst is concerned that cost overruns at the company's two LNG projects could reemerge, adding risk to 2017-2019 earnings.
08/11/17
FBCO
08/11/17
NO CHANGE
Target $13
FBCO
Neutral
CB&I price target lowered to $13 from $21 at Credit Suisse
Credit Suisse analyst Jamie Cook said that while CB&I's charges associated with Cameron and Freeport LNG and two gas fired power projects were expected, the $548M magnitude was bigger than expected. Also, unfortunately, since the two LNG projects are not expected to be complete until FY19, the market will "rightfully" remain concerned about potential additional charges, Cook tells investors. Cook lowered his FY17-19 estimates for CB&I and cut his price target on the stock to $13 from $21 while keeping a Neutral rating on the name.
08/10/17
DBAB
08/10/17
NO CHANGE
Target $21
DBAB
Buy
Deutsche Bank lays out path for CB&I shares getting back near $20
Deutsche Bank analyst Chad Dillard says that while CB&I's Q2 results "disappointed significantly," he sees a "clear path" to the shares trading towards the $20 range again should management execute and avoid further cos overruns. Selling the Technology business for 120% of the company's market value, deleveraging and reducing costs by $100M annually would unlock value, Dillard tells investors in a research note titled "2Q Results, A Tough (and Large) Pill to Swallow." The analyst lowered his price target for CB&I shares to $21 from $25 and maintains a Buy rating on the name. The stock in premarket trading is down 22%, or $3.58, to $12.75.

TODAY'S FREE FLY STORIES

FEYE

FireEye

$16.98

-0.16 (-0.93%)

, PANW

Palo Alto Networks

$141.75

-1.12 (-0.78%)

21:49
09/20/17
09/20
21:49
09/20/17
21:49
Hot Stocks
SEC discloses hack of Edgar system in 2016 »

Securities and Exchange…

FEYE

FireEye

$16.98

-0.16 (-0.93%)

PANW

Palo Alto Networks

$141.75

-1.12 (-0.78%)

QLYS

Qualys

$52.45

0.25 (0.48%)

CHKP

Check Point

$111.27

-1.71 (-1.51%)

PFPT

Proofpoint

$92.19

0.32 (0.35%)

FTNT

Fortinet

$38.24

-0.3 (-0.78%)

SYMC

Symantec

$33.72

-0.44 (-1.29%)

IMPV

Imperva

$44.45

-0.15 (-0.34%)

FFIV

F5 Networks

$116.83

0.07 (0.06%)

CUDA

Barracuda

$24.32

-0.15 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 10

    Oct

  • 18

    Oct

  • 19

    Oct

OMP

Oasis Midstream Partners

20:38
09/20/17
09/20
20:38
09/20/17
20:38
Syndicate
Oasis Midstream Partners 7.5M share IPO priced at $19.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLRN

Acceleron

$37.73

-1.24 (-3.18%)

20:37
09/20/17
09/20
20:37
09/20/17
20:37
Syndicate
Acceleron 5.405M share Secondary priced at $37.00 »

JPMorgan, Citi and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

IOVA

Iovance Biotherapeutics

$7.15

-1.4 (-16.37%)

19:46
09/20/17
09/20
19:46
09/20/17
19:46
Syndicate
Iovance Biotherapeutics 7.69M share Secondary priced at $6.50 »

The deal priced at $6.50,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 21

    Sep

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

, CAB

Cabela's

$61.45

0.07 (0.11%)

18:28
09/20/17
09/20
18:28
09/20/17
18:28
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P SmallCap 600…

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

CAB

Cabela's

$61.45

0.07 (0.11%)

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$86.37

-3.55 (-3.95%)

, TOSYY

Toshiba, also use TOSBF

$17.08

-0.29 (-1.67%)

18:26
09/20/17
09/20
18:26
09/20/17
18:26
Hot Stocks
Sandisk subsidiaries initiate new arbitration proceedings against Toshiba »

Western Digital (WDC)…

WDC

Western Digital

$86.37

-3.55 (-3.95%)

TOSYY

Toshiba, also use TOSBF

$17.08

-0.29 (-1.67%)

TOSBF

Toshiba, also use TOSYY

$2.87

-0.02 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOA

North American Energy

$4.10

-0.05 (-1.20%)

18:26
09/20/17
09/20
18:26
09/20/17
18:26
Hot Stocks
North American Energy awarded two earthworks contracts for $90M »

North American Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISTR

Investar Holding

$23.15

0.15 (0.65%)

18:01
09/20/17
09/20
18:01
09/20/17
18:01
Hot Stocks
Investar Holding raises quarterly dividend to 3c from 2c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$47.86

-0.63 (-1.30%)

17:56
09/20/17
09/20
17:56
09/20/17
17:56
Syndicate
Beacon Roofing 6.325M share Secondary priced at $47.50 »

BofA/Merrill, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

AMD

AMD

$13.74

0.62 (4.73%)

, AMPH

Amphastar

$15.64

-0.02 (-0.13%)

17:46
09/20/17
09/20
17:46
09/20/17
17:46
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: AMD (AMD), up 6%…

AMD

AMD

$13.74

0.62 (4.73%)

AMPH

Amphastar

$15.64

-0.02 (-0.13%)

GVP

GSE Systems

$2.80

0.05 (1.82%)

MLHR

Herman Miller

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

JUNO

Juno Therapeutics

$45.21

1.41 (3.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 28

    Sep

ABMD

Abiomed

$157.42

0.32 (0.20%)

17:36
09/20/17
09/20
17:36
09/20/17
17:36
Hot Stocks
Abiomed receives FDA PMA approval for Impella RP for right heart failure »

Abiomed has received FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSK

Oshkosh

$79.69

0.34 (0.43%)

17:35
09/20/17
09/20
17:35
09/20/17
17:35
Hot Stocks
Oshkosh awarded $466.7M government contract modification »

Oshkosh Defense, Oshkosh,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$155.03

-1.01 (-0.65%)

17:32
09/20/17
09/20
17:32
09/20/17
17:32
Hot Stocks
Aetna president Lynch sells $2.5M of company shares »

The president of health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$5.22

-0.29 (-5.26%)

17:25
09/20/17
09/20
17:25
09/20/17
17:25
Hot Stocks
Blue Apron jumps after meal kit competitor Plated acquired by Albertsons »

Earlier today, food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$91.68

-0.12 (-0.13%)

17:22
09/20/17
09/20
17:22
09/20/17
17:22
Earnings
Dr Pepper Snapple cuts FY17 EPS view to $4.53-$4.63 from $4.56-$4.66 »

FY17 consensus $4.63. In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$24.64

-0.07 (-0.28%)

17:22
09/20/17
09/20
17:22
09/20/17
17:22
Downgrade
Hanesbrands rating change at Nomura Instinet »

Hanesbrands downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

, SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

17:19
09/20/17
09/20
17:19
09/20/17
17:19
Hot Stocks
Breaking Hot Stocks news story on Third Point Reinsurance, Sanderson Farms »

Third Point Reinsurance…

TPRE

Third Point Reinsurance

$14.40

-0.1 (-0.69%)

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

, CAB

Cabela's

$61.45

0.07 (0.11%)

17:18
09/20/17
09/20
17:18
09/20/17
17:18
Hot Stocks
Sanderson Farms to replace Cabela's in S&P 400 at open on 9/26 »

Bass Pro Shops is…

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

CAB

Cabela's

$61.45

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:14
09/20/17
09/20
17:14
09/20/17
17:14
Hot Stocks
Intellipharmaceutics receives Nasdaq non-compliance notice »

Intellipharmaceutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RWLK

ReWalk Robotics

17:13
09/20/17
09/20
17:13
09/20/17
17:13
Syndicate
Breaking Syndicate news story on ReWalk Robotics »

ReWalk Robotics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABM

ABM

$39.29

0.23 (0.59%)

17:11
09/20/17
09/20
17:11
09/20/17
17:11
Hot Stocks
Breaking Hot Stocks news story on ABM »

Thomas H. Lee Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVTY

Invuity

$8.35

-0.15 (-1.76%)

17:07
09/20/17
09/20
17:07
09/20/17
17:07
Hot Stocks
Breaking Hot Stocks news story on Invuity »

Discovery Group raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Nov

USG

USG

$31.26

1.84 (6.25%)

, CBPX

Continental Building

$25.60

1.25 (5.13%)

17:04
09/20/17
09/20
17:04
09/20/17
17:04
Hot Stocks
Gypsum stocks jump after peer National Gypsum announces price increase »

Shares of companies…

USG

USG

$31.26

1.84 (6.25%)

CBPX

Continental Building

$25.60

1.25 (5.13%)

EXP

Eagle Materials

$105.07

2.9 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

TRHC

Tabula Rasa HealthCare

$25.66

-0.38 (-1.46%)

16:46
09/20/17
09/20
16:46
09/20/17
16:46
Recommendations
Tabula Rasa HealthCare analyst commentary at Piper Jaffray »

Tabula Rasa HealthCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

16:40
09/20/17
09/20
16:40
09/20/17
16:40
General news
Fed Leans into Wind on Balance Sheet: »

Fed Leans into Wind on…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.